Avoro Capital Advisors LLC Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Avoro Capital Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 33.3% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 400,000 shares of the biopharmaceutical company’s stock after purchasing an additional 100,000 shares during the period. Alnylam Pharmaceuticals accounts for approximately 1.3% of Avoro Capital Advisors LLC’s portfolio, making the stock its 19th largest position. Avoro Capital Advisors LLC owned 0.32% of Alnylam Pharmaceuticals worth $97,200,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. HighVista Strategies LLC purchased a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at approximately $632,000. Itau Unibanco Holding S.A. purchased a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $79,000. Profund Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 55.4% in the 2nd quarter. Profund Advisors LLC now owns 14,402 shares of the biopharmaceutical company’s stock worth $3,500,000 after purchasing an additional 5,132 shares in the last quarter. Summit Trail Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $226,000. Finally, Skandinaviska Enskilda Banken AB publ increased its position in shares of Alnylam Pharmaceuticals by 13.0% during the second quarter. Skandinaviska Enskilda Banken AB publ now owns 106,892 shares of the biopharmaceutical company’s stock valued at $25,967,000 after buying an additional 12,339 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 8,301 shares of the business’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99. Following the transaction, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In related news, CEO Yvonne Greenstreet sold 8,301 shares of the firm’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the transaction, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at $18,602,548.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares in the company, valued at approximately $35,632. The disclosure for this sale can be found here. Insiders have sold a total of 70,698 shares of company stock valued at $18,497,434 over the last ninety days. 1.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms have weighed in on ALNY. JPMorgan Chase & Co. upped their target price on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Morgan Stanley raised their price objective on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the company an “equal weight” rating in a research report on Friday, July 12th. UBS Group upped their target price on shares of Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the stock a “buy” rating in a research report on Friday, June 28th. Evercore ISI boosted their price objective on shares of Alnylam Pharmaceuticals from $210.00 to $260.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 25th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $220.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, September 9th. Seven equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $279.14.

Alnylam Pharmaceuticals Stock Down 0.9 %

NASDAQ ALNY opened at $273.88 on Monday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $287.55. The company has a market capitalization of $34.64 billion, a P/E ratio of -102.19 and a beta of 0.38. The stock’s 50-day moving average price is $260.11 and its 200-day moving average price is $199.42.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analysts’ expectations of $447.22 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 107.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.21) EPS. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.